Comparative Analysis, page-46

First 46 Last

Share
Profile

Follow
valueadd

6,478 Posts.

2054

28/01/25

19:13

Post #: 77592846
Share

Originally posted by Shellbell ↑

.... and what's more, the following suggests that if the science works in humans as it did in the animal models, our CAR-T-CDH17 therapy could get the monopoly on the Colorectal, various NET and a sizeable chunk of the Gastric Cancer markets. With the percentage of NET tumours expressing CDH17 protein being 100%, and the presence of the same protein in healthy tissue being hidden from detection, essentially means that our therapy has up to a potential 100% target rate within this area of unmet need. It also suggests to me, the diagnostic process is simplified (no need for a repertoire of biomarkers to determine a NET patient's suitability for our treatment). Its going to come down to how well it does its job in destroying 100% of the vulnerable NET tumours, 98% of Colorectal and 48% of Gastric Tumours.... ie. its efficacy rate. Bring on the data, please!

Expand

IF The scenario / question you posed were to happen .... & be recognized ...
these absurd prices we are seeing for CHM at the moment ...would become a very distant memory ...with many observers kicking them selves for not loading up ...

Whats 20 cent share price in terms of .06 ..... ahhh only a " 33 Bagger " ..and that just could be the start .

Nice to add a bit of fantasizing into ones life ...or maybe reality

LOL

( wheres Steini when u need him ? - NOT )

CHM Price at posting: 0.6¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce locks in $30M to boost commercialisation across ASEAN region

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

First 46 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.4¢		Change 0.000(0.00%)		Mkt cap ! $8.060M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.4¢	$100	25K

Buyers (Bids)

No.	Vol.	Price($)
28	21874000	0.4¢

Sellers (Offers)

Price($)	Vol.	No.
0.5¢	19510638	27

View Market Depth

No.	Vol.	Price($)
28	21874000	0.004
37	23631939	0.003
15	13500507	0.002
9	49600000	0.001
0	0	0.000

Price($)	Vol.	No.
0.005	19510638	27
0.006	23500718	17
0.007	4700000	4
0.008	8542434	6
0.009	2767672	5

Last trade - 15.25pm 17/06/2025 (20 minute delay)

CHM (ASX) Chart

Comparative Analysis, page-46

Recce locks in $30M to boost commercialisation across ASEAN region

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Comparative Analysis, page-46

Top Stories

Recce locks in $30M to boost commercialisation across ASEAN region

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News